GH Max Stack

The GH Max Stack represents the most aggressive non-exogenous approach to maximizing growth hormone output, combining three distinct mechanisms of GH stimulation. CJC-1295 with DAC (Drug Affinity Complex) is a modified GHRH analog conjugated to a protein that extends its half-life to approximately 8 days. Unlike the no-DAC version, it provides a sustained elevation of baseline GH levels rather than discrete pulses, creating a continuously elevated "floor" of GH secretion throughout the week. MK-677 (Ibutamoren) is an orally active, non-peptide ghrelin receptor agonist with a 24-hour half-life. It provides continuous GHS-R1a activation, complementing the sustained GHRH signaling from CJC-1295 with DAC. Clinical trials have demonstrated MK-677 increases IGF-1 levels by 40-60% in elderly subjects and improves nitrogen balance — a surrogate for anabolic activity. Daily Ipamorelin injections add targeted GH pulses on top of the elevated baseline, creating both sustained elevation and superimposed pulsatile peaks. This triple-mechanism approach produces GH and IGF-1 levels that approach or exceed physiological youth ranges. However, the advanced classification reflects significant considerations: MK-677 substantially increases appetite (via ghrelin pathway activation), may raise fasting blood glucose and HbA1c over time, and can cause water retention. The sustained GH elevation from CJC-1295 with DAC means less receptor recovery time compared to pulsatile protocols. This stack requires regular monitoring of fasting glucose, IGF-1 levels, and ideally HbA1c every 3 months. It is contraindicated in individuals with diabetes, pre-diabetes, active malignancy, or family history of pituitary tumors.